Mindray

Mindray is a Chinese medical technology company that designs, manufactures, and distributes a wide range of diagnostic and therapeutic equipment. Its product portfolio includes patient monitoring systems, ultrasound imaging devices, in‑vitro diagnostics reagents and analyzers, as well as life support and anesthesia equipment. The company serves healthcare providers such as hospitals, clinics, and emergency medical services across multiple clinical departments. Mindray’s solutions are intended to support critical care, obstetrics, cardiology, and general diagnostics. Its offerings are marketed to both public and private healthcare institutions worldwide.

Founded in 1991 and headquartered in Shenzhen, Mindray has expanded its operations to a global scale. The company maintains subsidiaries, representative offices, and service centers in more than thirty countries across Asia, Europe, the Americas, and Africa. Its products are distributed through a network of local partners and direct sales teams that adapt to regional regulatory requirements. Mindray is listed on the Shenzhen Stock Exchange under the ticker 300760.SZ, reflecting its status as a publicly traded enterprise. This listing provides the company with access to capital for continued investment in research and development.

Mindray distinguishes itself through a strong emphasis on innovation, allocating a significant portion of its revenue to research and development and holding thousands of patents related to medical imaging and monitoring technologies. The firm has earned recognition as a leading supplier of medical devices in China and has increasingly competed with established multinational corporations in international markets. Its products are designed to meet stringent regulatory standards such as CE marking in Europe and FDA clearance in the United States, enabling global market access. Structurally, Mindray operates as an independent, publicly listed company without a dominant parent entity or major subsidiary hierarchy. The company’s profile was further highlighted in 2026 when it was named among the victims of a Cl0p ransomware campaign that exploited a vulnerability in PTC’s Windchill platform.